Life Sciences

Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies
7 October 2020

Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies

Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million...

Read more
LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding
29 September 2020

LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding

LARQ was started with a simple vision where innovative technology can be combined with inspirational design to help people access pristine drinking water easily and...

Read the press release
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
25 September 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...

Read more
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23 September 2020

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read more
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
22 September 2020

Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in...

Read more
LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases
9 September 2020

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases

LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that...

Read more
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9 September 2020

Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read more
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
2 September 2020

BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease

As part of the collaboration, BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the aim of identifying biomarkers using the XMarker...

Read more
Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field
30 July 2020

Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field

Seventure Partners, a European leader in financing innovation, announces today that the technical committee of the French government initiative, which was set up to support...

Read the press release